We see our prime role as reducing risk and increasing success rates for early start-ups. We aim to do this by filling the current commercial management resource gap between the TTO spinout and venture capitalist investment stages. This enables us to create a balanced product portfolio with an optimized risk/return profile; a portfolio full of opportunity for international biomedical investors.

BMI was founded in 2004 as a joint venture between Medinnova and Oslo Research Park.  In 2005 BMI signed a development and licensing agreement with GlaxoSmithKline for the use of piboserod in chronic heart failure.  BMI raised about 45 MNOK of private and public capital for the completion of its clinical phase II trial on piboserod.  In 2008 BMI signed a preferred partner agreement with Medinnova and acquired a portfolio of start-ups and projects from RF.  Additional capital of 20 MNOK was raised in April 2008.